Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus. The group B strep test is the second in the ...

Most readers would already be aware that Meridian Bioscience's (NASDAQ:VIVO) stock increased significantly by 9.0% over the past month. Given the company's impressive performance, we decided to study ...

New CEO, CFO, and EVP of Life Science named to drive strategic execution across Diagnostics and Life Science. CINCINNATI, Oct. 14, 2025 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global ...

New formats redefine molecular assay development by cutting refrigeration costs, simplifying logistics, and ensuring uncompromised performance at room temperature. For decades, the molecular ...

Cincinnati, Ohio life sciences company Meridian Bioscience Inc. (NASDAQ: VIVO) has acquired the outstanding capital stock of Bioline Ltd., the London, England-based maker and distributor of molecular ...

(RTTNews) - Meridian Bioscience Inc. (VIVO) said that it agreed to be acquired by SD Biosensor and SJL Partners in $1.53 billion all-cash transaction. As per the terms of the deal, Meridian ...

CINCINNATI, April 30, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, has completed its previously ...

Resolve Biosciences Molecular Cartography™ technology was used to spatially resolve distinct cell populations by using specific gene markers in the perivascular niche microenvironment in a mouse ...

Meridian Bioscience (Nasdaq: VIVO) reported earnings on Jan. 25. Here are the numbers you need to know. The 10-second takeaway For the quarter ended Dec. 31 (Q1), Meridian Bioscience missed on ...

In this series, we measure how swiftly a company turns cash into goods or services and back into cash. We'll use a quick, relatively foolproof tool known as the cash conversion cycle, or CCC for short ...